ADPT [NASD]
Adaptive Biotechnologies Corporation
Index- P/E- EPS (ttm)-1.63 Insider Own2.50% Shs Outstand141.70M Perf Week9.28%
Market Cap1.17B Forward P/E- EPS next Y-1.62 Insider Trans-2.18% Shs Float139.85M Perf Month8.85%
Income-229.40M PEG- EPS next Q-0.43 Inst Own87.00% Short Float4.54% Perf Quarter-36.27%
Sales154.50M P/S7.54 EPS this Y-32.50% Inst Trans1.81% Short Ratio3.50 Perf Half Y-69.35%
Book/sh3.90 P/B2.11 EPS next Y1.20% ROA-24.10% Target Price15.30 Perf Year-80.57%
Cash/sh2.57 P/C3.20 EPS next 5Y8.30% ROE-36.70% 52W Range5.95 - 43.40 Perf YTD-70.63%
Dividend- P/FCF- EPS past 5Y- ROI-34.60% 52W High-81.01% Beta-
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin66.00% 52W Low38.37% ATR0.70
Employees858 Current Ratio3.60 Sales Q/Q0.50% Oper. Margin- RSI (14)53.83 Volatility9.50% 9.47%
OptionableYes Debt/Eq0.00 EPS Q/Q-51.40% Profit Margin- Rel Volume0.76 Prev Close8.60
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume1.81M Price8.24
Recom1.90 SMA209.95% SMA502.24% SMA200-58.91% Volume1,368,953 Change-4.19%
Jun-03-22Initiated Piper Sandler Neutral $7.50
Feb-16-22Reiterated JP Morgan Overweight $75 → $50
Feb-16-22Reiterated Goldman Neutral $54 → $21
Feb-16-22Reiterated BTIG Research Buy $35 → $30
Feb-16-22Reiterated BofA Securities Buy $40 → $32
Oct-15-21Resumed Cowen Outperform
Mar-03-21Downgrade Goldman Buy → Neutral $74 → $63
Oct-08-20Resumed BTIG Research Buy $60
Sep-09-20Initiated Morgan Stanley Equal-Weight $42
Jun-03-20Initiated Goldman Buy $60
Jul-23-19Initiated BTIG Research Buy $46
Jul-22-19Initiated William Blair Outperform
Jul-22-19Initiated Guggenheim Buy $47
Jul-22-19Initiated Goldman Neutral $32
Jul-22-19Initiated Cowen Outperform
Jul-22-19Initiated BofA/Merrill Buy $45
Jun-16-22 12:49PM  
Jun-15-22 07:30AM  
Jun-10-22 05:00PM  
Jun-03-22 10:09AM  
Jun-02-22 04:10PM  
May-31-22 11:42AM  
May-26-22 08:00AM  
May-13-22 10:35AM  
May-04-22 10:30PM  
06:35PM  
04:05PM  
09:59AM  
May-02-22 04:05PM  
Apr-05-22 04:30PM  
Mar-31-22 11:16AM  
05:46AM  
Mar-25-22 04:54PM  
01:24PM  
Mar-22-22 10:10AM  
Mar-11-22 12:43PM  
Mar-10-22 10:15AM  
Mar-09-22 10:37AM  
07:00AM  
01:34AM  
Mar-02-22 04:05PM  
Feb-22-22 11:21AM  
Feb-18-22 11:35AM  
09:21AM  
Feb-15-22 07:30PM  
05:55PM  
04:09PM  
04:05PM  
Feb-08-22 03:00PM  
04:26AM  
Feb-02-22 04:05PM  
Jan-31-22 01:12PM  
10:00AM  
Jan-25-22 05:38PM  
10:00AM  
Jan-24-22 04:05PM  
01:38PM  
Jan-20-22 10:39AM  
Jan-12-22 10:42AM  
Jan-10-22 08:30AM  
Jan-04-22 04:05PM  
Jan-03-22 07:00PM  
Dec-29-21 08:00AM  
Dec-22-21 11:11AM  
Dec-13-21 04:05PM  
Dec-12-21 10:41PM  
Dec-10-21 04:33AM  
Dec-02-21 08:00AM  
Nov-29-21 06:44AM  
Nov-25-21 05:57AM  
Nov-12-21 07:40AM  
Nov-11-21 05:52PM  
Nov-04-21 08:00AM  
03:01AM  
Nov-03-21 05:45PM  
04:05PM  
Oct-27-21 03:03PM  
Oct-18-21 05:27AM  
Oct-11-21 03:55PM  
06:02AM  
Oct-08-21 11:57AM  
Oct-06-21 04:05PM  
Oct-02-21 01:15PM  
Sep-30-21 07:30AM  
Sep-21-21 04:05PM  
Sep-16-21 11:24AM  
08:03AM  
Sep-13-21 11:19AM  
Sep-10-21 04:55PM  
Sep-07-21 05:15PM  
Aug-15-21 06:17AM  
Aug-12-21 01:19AM  
Aug-10-21 02:11PM  
Aug-05-21 09:01AM  
Aug-04-21 06:25PM  
04:15PM  
04:05PM  
Jul-28-21 03:03PM  
Jul-19-21 09:54AM  
05:20AM  
Jul-17-21 09:15AM  
Jul-12-21 04:05PM  
Jul-06-21 11:21AM  
Jun-30-21 11:17AM  
Jun-23-21 12:00PM  
Jun-16-21 08:00AM  
Jun-09-21 07:15AM  
Jun-03-21 07:30AM  
May-21-21 09:55AM  
May-20-21 04:05PM  
May-18-21 09:16AM  
08:07AM  
May-17-21 12:17PM  
May-11-21 11:30AM  
11:21AM  
09:18AM  
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ADAMS R MARKChief Operating OfficerApr 07Sale13.1783110,944122,893Apr 08 08:00 PM
ROBINS CHAD MCEO and ChairmanMar 09Sale12.4614,815184,5951,916,154Mar 09 07:00 PM
BALDO LANCEChief Medical OfficerMar 08Sale11.433,35038,29017,171Mar 10 06:00 PM
Taylor Stacy LSVP and General CounselMar 08Sale11.442,38727,30772,859Mar 10 09:00 PM
LO FRANCISChief People OfficerMar 08Sale11.443,58240,97889,588Mar 10 04:05 PM
ROBINS CHAD MCEO and ChairmanMar 08Sale11.3814,815168,5951,916,154Mar 09 07:00 PM
ROBINS CHAD MCEO and ChairmanMar 07Option Exercise6.3214,81593,6311,930,969Mar 09 07:00 PM
ADAMS R MARKChief Operating OfficerMar 07Sale12.011,24414,940123,724Mar 08 09:00 PM
ROBINS CHAD MCEO and ChairmanMar 07Sale12.014,42453,1321,916,154Mar 08 09:00 PM
ROBINS HARLAN SChief Scientific OfficerMar 07Sale12.014,51754,249311,960Mar 08 09:00 PM
LO FRANCISChief People OfficerMar 07Sale12.011,56918,84493,170Mar 08 09:00 PM
PISKEL KYLEPrincipal Accounting OfficerMar 07Sale12.012202,64247,665Mar 08 09:00 PM
Taylor Stacy LSVP and General CounselMar 07Sale12.011,56918,84475,246Mar 08 09:00 PM
ROBINS CHAD MCEO and ChairmanMar 07Sale11.5514,815171,1621,916,154Mar 09 07:00 PM
BENZENO SHARONChief Business Development OffMar 07Sale12.012,67032,067102,596Mar 08 09:01 PM
RUBINSTEIN JULIEPresidentMar 07Sale12.014,61355,402226,513Mar 08 09:01 PM
BALDO LANCEChief Medical OfficerMar 07Sale12.012,37328,50020,521Mar 08 09:01 PM
ADAMS R MARKChief Operating OfficerJan 07Sale23.321,02123,81050,833Jan 10 08:00 PM
Taylor Stacy LSVP and General CounselDec 22Option Exercise6.9715,338106,97430,374Dec 23 09:00 PM
Cohen Chad MChief Financial OfficerDec 22Option Exercise7.2710,00072,70031,604Dec 23 09:00 PM
Taylor Stacy LSVP and General CounselDec 22Sale30.0015,338460,14015,036Dec 23 09:00 PM
Cohen Chad MChief Financial OfficerDec 22Sale30.0010,000300,00021,604Dec 23 09:00 PM
ROBINS HARLAN SChief Scientific OfficerNov 18Option Exercise6.553001,96569,660Nov 19 04:59 PM
ROBINS HARLAN SChief Scientific OfficerNov 18Sale31.363009,40869,360Nov 19 04:59 PM
ROBINS HARLAN SChief Scientific OfficerNov 17Option Exercise6.553,70024,23573,060Nov 19 04:59 PM
ROBINS HARLAN SChief Scientific OfficerNov 17Sale32.053,700118,58569,360Nov 19 04:59 PM
Cohen Chad MChief Financial OfficerNov 10Option Exercise7.275,00036,35026,604Nov 12 05:00 PM
Cohen Chad MChief Financial OfficerNov 10Sale33.935,000169,65021,604Nov 12 05:00 PM
Cohen Chad MChief Financial OfficerNov 09Option Exercise7.275,00036,35026,604Nov 12 05:00 PM
Cohen Chad MChief Financial OfficerNov 09Sale36.035,000180,15021,604Nov 12 05:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 21Option Exercise6.553,70024,23573,060Oct 21 09:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 21Sale33.733,700124,80169,360Oct 21 09:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 20Option Exercise6.553,70024,23573,060Oct 21 09:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 20Sale33.713,700124,72769,360Oct 21 09:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 19Option Exercise6.553,80024,89073,160Oct 21 09:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 19Sale33.693,800128,03369,360Oct 21 09:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 08Option Exercise6.323,89524,61673,255Oct 08 07:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 08Sale32.963,895128,37969,360Oct 08 07:00 PM
ADAMS R MARKChief Operating OfficerOct 08Sale33.671,80160,64051,854Oct 08 07:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 07Option Exercise6.323,89524,61673,255Oct 08 07:00 PM
ADAMS R MARKChief Operating OfficerOct 07Sale32.471,32442,99053,655Oct 08 07:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 07Sale33.623,895130,94869,360Oct 08 07:00 PM
Cohen Chad MChief Financial OfficerOct 06Option Exercise7.275,00036,35026,604Oct 07 07:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 06Option Exercise6.323,89524,61673,255Oct 08 07:00 PM
ROBINS HARLAN SChief Scientific OfficerOct 06Sale32.273,895125,69269,360Oct 08 07:00 PM
Cohen Chad MChief Financial OfficerOct 06Sale32.305,000161,50021,604Oct 07 07:00 PM
Cohen Chad MChief Financial OfficerOct 05Option Exercise7.275,00036,35026,604Oct 07 07:00 PM
Cohen Chad MChief Financial OfficerOct 05Sale32.515,000162,55021,604Oct 07 07:00 PM
ROBINS HARLAN SChief Scientific OfficerSep 15Option Exercise6.323,89524,61673,255Sep 15 07:51 PM
ROBINS HARLAN SChief Scientific OfficerSep 15Sale36.683,895142,88469,360Sep 15 07:51 PM
ROBINS HARLAN SChief Scientific OfficerSep 14Option Exercise6.323,89524,61673,255Sep 15 07:51 PM
ROBINS HARLAN SChief Scientific OfficerSep 14Sale36.743,895143,08669,360Sep 15 07:51 PM
ROBINS HARLAN SChief Scientific OfficerSep 13Option Exercise6.323,89524,61673,255Sep 15 07:51 PM
ROBINS HARLAN SChief Scientific OfficerSep 13Sale37.513,895146,08469,360Sep 15 07:51 PM
ROBINS CHAD MCEO and ChairmanSep 10Sale38.385,000191,9211,673,461Sep 10 09:00 PM
ROBINS CHAD MCEO and ChairmanSep 09Sale38.4224,753951,0101,678,461Sep 10 09:00 PM
Cohen Chad MChief Financial OfficerSep 08Option Exercise7.275,00036,35026,604Sep 09 07:00 PM
ROBINS CHAD MCEO and ChairmanSep 08Sale38.4513,746528,5651,703,214Sep 10 09:00 PM
Cohen Chad MChief Financial OfficerSep 08Sale39.015,000195,05021,604Sep 09 07:00 PM
Taylor Stacy LSVP and General CounselSep 07Option Exercise6.554953,24215,531Sep 09 07:00 PM
Cohen Chad MChief Financial OfficerSep 07Option Exercise6.559,37561,40630,979Sep 09 07:00 PM
Taylor Stacy LSVP and General CounselSep 07Sale40.0049519,80015,036Sep 09 07:00 PM
Cohen Chad MChief Financial OfficerSep 07Sale39.719,375372,28121,604Sep 09 07:00 PM
ROBINS HARLAN SChief Scientific OfficerAug 27Option Exercise6.323,89524,61673,255Aug 27 09:00 PM
GRIFFIN MICHELLE RENEEDirectorAug 27Option Exercise7.8014,916116,34516,420Aug 30 08:00 PM
GRIFFIN MICHELLE RENEEDirectorAug 27Sale35.0014,916522,0601,504Aug 30 08:00 PM
ROBINS HARLAN SChief Scientific OfficerAug 27Sale34.783,895135,44969,360Aug 27 09:00 PM
ROBINS HARLAN SChief Scientific OfficerAug 26Option Exercise6.323,89524,61673,255Aug 27 09:00 PM
ROBINS HARLAN SChief Scientific OfficerAug 26Sale33.893,895132,00269,360Aug 27 09:00 PM
ROBINS HARLAN SChief Scientific OfficerAug 25Option Exercise6.323,89524,61673,255Aug 27 09:00 PM
ROBINS HARLAN SChief Scientific OfficerAug 25Sale34.093,895132,78169,360Aug 27 09:00 PM
Cohen Chad MChief Financial OfficerAug 11Option Exercise6.5510,00065,50031,604Aug 12 08:00 PM
Cohen Chad MChief Financial OfficerAug 11Sale33.6010,000336,04921,604Aug 12 08:00 PM
Cohen Chad MChief Financial OfficerAug 10Option Exercise6.555,00032,75026,604Aug 12 08:00 PM
Cohen Chad MChief Financial OfficerAug 10Sale35.005,000175,00021,604Aug 12 08:00 PM
ROBINS HARLAN SChief Scientific OfficerJul 21Option Exercise6.323,89524,61673,255Jul 21 09:00 PM
ROBINS HARLAN SChief Scientific OfficerJul 21Sale37.823,895147,29069,360Jul 21 09:00 PM
ROBINS HARLAN SChief Scientific OfficerJul 20Option Exercise6.323,89524,61673,255Jul 21 09:00 PM
ROBINS HARLAN SChief Scientific OfficerJul 20Sale37.483,895145,99669,360Jul 21 09:00 PM
Palaniappan JyotiSVP, Diagnostics, T-DetectJul 19Option Exercise22.5565114,6809,809Jul 19 09:00 PM
ROBINS HARLAN SChief Scientific OfficerJul 19Option Exercise6.323,89524,61673,255Jul 21 09:00 PM
ROBINS HARLAN SChief Scientific OfficerJul 19Sale37.123,895144,59869,360Jul 21 09:00 PM
Palaniappan JyotiSVP, Diagnostics, T-DetectJul 19Sale36.1265123,5149,158Jul 19 09:00 PM
GRIFFIN MICHELLE RENEEDirectorJul 14Option Exercise7.802,50019,5004,004Jul 19 09:00 PM
GRIFFIN MICHELLE RENEEDirectorJul 14Sale36.802,50092,0001,504Jul 19 09:00 PM
ROBINS CHAD MCEO and ChairmanJul 12Sale38.241,50157,3981,716,960Jul 14 09:00 PM
ADAMS R MARKChief Operating OfficerJul 08Sale36.302,25481,82054,979Jul 08 09:00 PM
Cohen Chad MChief Financial OfficerJul 07Option Exercise6.5510,00065,50031,604Jul 08 09:00 PM
ADAMS R MARKChief Operating OfficerJul 07Sale39.4287134,33557,233Jul 08 09:00 PM
Cohen Chad MChief Financial OfficerJul 07Sale38.5310,000385,31921,604Jul 08 09:00 PM
Cohen Chad MChief Financial OfficerJul 06Option Exercise6.5510,00065,50031,604Jul 08 09:00 PM
Cohen Chad MChief Financial OfficerJul 06Sale38.8310,000388,30021,604Jul 08 09:00 PM
Taylor Stacy LSVP and General CounselJun 30Option Exercise15.044,16762,66319,203Jul 01 09:00 PM
Taylor Stacy LSVP and General CounselJun 30Sale41.424,167172,61415,036Jul 01 09:00 PM